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It has been nearly a century since the early description of microglia by Rio-Hortega; since then many more
biological and pathological features of microglia have been recognized. Today, microglia are generally considered
to be beneficial to homeostasis at the resting state through their abilities to survey the environment and
phagocytose debris. However, when activated microglia assume diverse phenotypes ranging from fully inflamed,
which involves the release of many pro-inflammatory cytokines, to alternatively activated, releasing anti-
inflammatory cytokines or neurotrophins, the consequences to neurons can range from detrimental to supportive.
Due to the different experimental sets and conditions, contradictory results have been obtained regarding the
controversial question of whether microglia are “good” or “bad.” While it is well understood that the dual roles of
activated microglia depend on specific situations, the underlying mechanisms have remained largely unclear, and
the interpretation of certain findings related to diverse microglial phenotypes continues to be problematic. In this
review we discuss the functions of microglia in neuronal survival and neurogenesis, the crosstalk between microglia
and surrounding cells, and the potential factors that could influence the eventual manifestation of microglia.
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Microglia are generally considered the immune cells of
the central nervous system (CNS) and account for 10%
of the total glial cell population in the brain. In a normal
physiological environment, they work as sentinel cells by
continually screening the brain tissue; they actively par-
ticipate in pathological processes by changing morph-
ology, expressing various antigens and becoming
phagocytic. During the past 20 years, thousands of papers
have been published describing both the detrimental and
beneficial roles of microglia in various brain disorders,
from acute infection or stroke to the long and chronic
process of neurodegeneration. Microglia have been firmly
established as a key cellular component involved in the
eventual outcome of inflammation and eventually contrib-
ute to the chronic neurodegeneration; The physiology and
signaling of microglia have been comprehensively reviewedtd. This is an Open Access article distributed under the terms of the Creative
mons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
al work is properly cited.
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of microglial activity is a highly complex system, and the
responses of microglia are tailored in a multi-factor
dependent manner, and which are the focus we try to re-
view in this paper.
The origin of microglia
The precise origin and cell lineage of microglia has been a
long time debate. So far two most important hypotheses for
microglial origin have been held: “neuroectodermal” or
“myeloid-monocytic”. Even though the latter has been more
widely accepted now, the neuroectodermal hypothesis
remains interesting. Skoff [7] detected “multipotential glia
cell” with a rat model of optic nerve degeneration and optic
nerve development, these cells were demonstrated to ori-
ginate from neuroectodermal matrix cells, and Kitamura
later confirmed this result by describing a continuous mor-
phological transition between glioblasts and ramified micro-
glia in the developing gray matter of hippocampus [8]. The
hematopoietic origin of microglia also received a lot atten-
tion, the presence of bone marrow Mac-1 positive cells
were demonstrated in the brain of embryonic and adult
mice, and these cells were proved to be the progenitors for
microglial cells [9], also transplantation of GFP+mice bone
marrow cells in GFP- host mice revealed the presence of
many GFP+microglia throughout developing and/or
inflamed CNS [10,11], which strongly suggest the
hematopoietic stem cells as one of the origins for replenish-
ment of microglia in the neuropathology. Additionally due
to the high similarity in marker expression and phagocytosis
behavior between circulating monocytes and microglia,
people speculate the monocytic origin of microglia, and a
couple of experiments have been performed to show the ap-
pearance of labeled monocytes in the developing [12] or
inflamed brain [13]. In many cases, the peripheral macro-
phages are considered to be the orthologue [14,15] or
backup of microglia and infiltrate the brain to supplement
microglia, thus to some extent peripheral macrophages mir-
ror the behavior of microglia in the brain and Monocyte-
derived Macrophages (MDMs) from patients have been
used as a substitute of microglia in many studies [16-18].
Microglia: the dual natures of neurotoxicity and
neuroprotection
Neuroinflammation has long been considered a mediator
of secondary damage following a small injury to the CNS.
As the primary immune cells in the brain, microglia are
expected to take active roles in the damage process. The
presence of activated microglia within injured brain regions
and in post-mortem tissue from patients having various
neurodegenerative disorders has led to the assumption that
all reactive microglia contribute to an adverse and degen-
erative process. Further studies describe destructive roles
for microglia by demonstrating the release of a range ofneurotoxins from microglia that includes pro-inflammatory
cytokines [19-21], nitric oxide [22,23] and reactive oxygen
species [24,25]; the inhibition of microglial activation in
various experiments results in the attenuation of neuro-
toxic events and improves neuronal survival. In various
neurodegenerative disorders, the over-activation of micro-
glia is considered to be a key causative factor in the process
or, at a minimum, to promote the neuropathology. For ex-
ample, in Alzheimer’s disease, microglia activated by amyl-
oid-β(Aβ) protein, the hallmark of the disease, release
neurotoxins and potentiate neuronal damage, and this
microglial over-activation is an early event that precedes
neuropil destruction [26]. The activated microglia cluster
around or penetrate the neuritic plaques [27], supporting a
critical role of microglial activation in the pathogenesis and
progression of the disease. In Parkinson’s disease (PD), an
increased number of activated microglia are present in the
vicinity of degenerating neurons [28] in the substantia
nigra [29], which is particularly deleterious to dopamin-
ergic neurons due to their glutathione deficiency [30]. A
single injection of lipopolysaccharide (LPS) to activate
microglia in the substantia nigra region led to a progres-
sive, preferential and irreversible loss of dopaminergic neu-
rons [31-33], even though LPS itself did no direct harm to
the neurons, indicating that the over-activation of micro-
glia is capable of inducing neuronal death in the absence of
other pathological stimulation. All of the evidence
described above supports the hypotheses of the neurotoxic
features of microglia.
However, as the sentinel and essential cells of the CNS,
it is unlikely that microglia would function to damage neu-
rons in all scenarios. Once stimulated the microglia mi-
grate rapidly to the injury site along the chemokine
gradients in vitro [34] and also in response to chemoat-
tractants including ATP and NO released directly or indir-
ectly by the injury [35] to exert effect on the survival of
neurons. In fact, some specifically designed experiments
have begun to uncover the neuroprotective roles of micro-
glia, and more studies are emerging to show beneficial
functions of microglia. Firstly, studies have demonstrated
instructive roles for microglia in the developing brain for
neuronal differentiation [36,37] and in the regulation of
neuronal apoptosis [38] through the production of neuro-
trophins [39]. Secondly, in the adult brain, resting micro-
glia, which are characterized by many fine perpendicular
processes extending from a few long prolongations, have
been regarded as sensor cells for the detection of abnor-
malities or changes in the brain [40] and help to maintain
environmental homeostasis. Lastly but most importantly,
activated microglia have also been shown to perform
neurotrophic functions following neuronal injury. One
compelling study supporting this finding involves the axot-
omy of peripheral nerves (facial or optic), where a rapid
microglial response is exhibited with the efficient clearance





hypoxia Morigiwa et al., 2000 [51]
tumor Bosco et al., 2011[52]
Ischemic insult Hur et al., 2010 [53]
Nerve injury Maeda et al., 2010 [54]
Proteins
α-synuclein Lee et al., 2010; Su et al., 2008;
Zhang et al., 2005 [55-57]
amyloid-beta Jana et al., 2008 [58]
fibrinogen Piers et al., 2011 [59]
Thrombin Lee et al., 2005 [60]
Tissue plasminogen activator Siao et al., 2002 [61]
Matrix protein
(vitronectin, fibronectin, MMP-3)
Milner et al., 2007;
del Zoppo et al., 2007;
Kim et al., 2005 [62-64]
Chemicals
Adenosine Triphosphate Matsui et al., 2011 [65]
Toxins (MPTP,
Rotenone, Paraquat)
Yasuda et al., 2008;
Gao et al., 2002;
Wu et al., 2005 [66-68]
Alchohol McClain et al., 2011 [69]
Dopamine quinone Kuhn et al., 2006 [70]
Berberine Lu et al., 2010 [71]
lipopolysacchride Jung et al., 2010;
Meng et al., 2008;
Xu et al., 2009 [72-74]
Cytokines
TNF-α Iribarren et al., 2005 [75]
IL-6 Krady et al., 2008 [76]
IL-12 Tamakawa et al., 2004 [77]
IL-3 Natarajan et al., 2004 [78]
IFN-Υ Rozenfeld et al., 2005;
Hall et al., 1999 [79,80]
Others
gangliosides Kim et al., 2009;
Min et al., 2004 [81,82]
Kalic acid Zheng et al., 2010;
Zhu et al., 2010 [83,84]
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axon growth, finally leading to successful axonal regener-
ation [41]; the inhibition of this microglial response to fa-
cial nerve axotomy impairs neuronal survival [42]. In
addition, in neonatal mice administered MPTP, highly acti-
vated microglia show neurotrophic potential towards
dopamine neurons [43] and after traumatic injury, clear
glutamate without evoking inflammatory mediators [44].
The benefits of microglial activation are further demon-
strated by the exacerbation of neuropathology in inducible
mouse models that are deficient in microglia [45,46], the
finding of protective microglia in cases of cerebral ische-
mia [47] and multiple sclerosis [48] and the fact that trans-
plantation of microglia can help to enhance neurite
growth and functional recovery after CNS injury [49,50].
The bunch of factors that can activate microglia and the
differential behavior of microglia in various conditions
have been listed in Table 1 & 2. The above studies clearly
demonstrate that microglia can be neurotrophic in the
proper situations; there might be a third possibility that
microglia are activated by simply reacting to pathogenic
stimulation and takes very limited roles in the neurological
disorders, in such case the activation of microglia is solely
a result of pathogenic stimulation and work as a by-
stander that either involved passively during the whole
process or even go to apoptosis by some other signals.
Thus These activated microglia might have different phe-
notypes. However, the details of what conditions induce
microglia to take beneficial phenotypes remain unknown.
Many factors are likely involved in determining the even-
tual outcome of the manifestation of microglia, including
their interaction with neurons or astrocytes in the same
environment, age-related dysfunction of microglia, activa-
tion timing, and the activation state of the microglia,
which we will be discussing below.
Crosstalk between microglia and other brain cells
Microglia have been considered to be the first line of
defense in the CNS [91], a hypothesis that has been sup-
ported by the finding that microglia actively screen their
microenvironment with highly motile processes; thus, the
brain is under continual surveillance by microglia. To do
this with high efficiency, microglia must be variable, adap-
tive to their environment and capable of integrating vari-
ous inputs and responding appropriately [92,93]. All of
these processes require significant interactions with other
components within the same environment, including neu-
rons and astrocytes.
Crosstalk between microglia and neurons: neurons as
regulators of microglial activation
When we talk about whether microglia are neuroprotective
or neurotoxic, we only refer to the influence of microglia on
neurons. However, many studies indicate that neurons arenot merely passive targets of microglia but rather exert con-
trol over microglial activities [94]. There are considerable
interactions between neurons and microglia. For example,
Polazzi hypothesized that activation of microglia as a conse-
quence of neuronal injury is primarily aimed at neuropro-
tection, with the loss of specific communications between
neurons and microglia leading to the neurotoxic behavior
of microglia [95]. Accumulating evidence demonstrates that
there is significant information exchange between neurons
and microglia. Depending on whether they are healthy or
injured, neurons send “on” or “off” signals to influence
microglial activation. On one hand, the activation of





Surveillance, homeostasis [85] Fixed cell and
motile processes, minimal expression of cell
surface markers and release of cytokines





Efficient clearance of myelin debris [41]
Traumatic injury Clear glutamate without evoking
inflammatory mediators [44]
Ischemia Synthesis of tumor necrosis factor,
engulfment of harmful invading neutrophil
granulocytes [86]
Alzheimer’s Disease Internalize and degrade amyloid beta [87]
Multiple sclerosis Secrete soluble mediators that trigger
neural repair and usually contribute to the
creation of an environment conductive for
regeneration [48]
Neurotoxic
Parkinson’s disease Releasing various kinds of noxious cytokines,
reactive oxygen species [88]
Multiple sclerosis Express iNOS [89] and generate toxic ROS
which might injure neurons
Alzheimer’s disease Produce of chemokines, neurotoxic
cytokines and reactive oxygen an dnitrogen
species that are deletrious to the CNS [90]
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widely reported [91,96]. On the other hand, in the healthy
brain, microglial activation is tightly restricted by signaling
from neurons. CD200-CD200R has been identified as one
of the critical pathways in attenuating microglial activation.
CD200 is a member of the immunoglobulin superfamily
and is expressed on the neuronal membrane surface, while
the CD200 receptor (CD200R) is primarily present in the
macrophage lineage, which includes microglia [97]. The
disruption of CD200-CD200R interactions results in an
accelerated microglial response, whereas intensified
CD200-CD200R interactions contribute to an attenu-
ation in neurodegeneration [98]. In mice that have had
CD200 selectively removed from neurons, microglia
exhibited an activated phenotype and were numerous
upon facial nerve transaction; damaged CD200-deficient
neurons elicited an accelerated microglial response,
which demonstrated a loss of the neuronal inhibitory
signal for microglial response [97]. Apart from direct
interactions through receptor-ligand combinations,
electrical activity and soluble factors released from in-
tact neurons also maintain microglial quiescence. In a
neuron-glia co-culture, the blockade of neuronal elec-
trical activity by tetrodotoxin or a glutamate receptor
antagonist facilitated microglial activation induced by
IFN-γ [99]. Soluble molecules from neurons such asneurotrophins and anti-inflammatory agents down-
regulate antigen expression on cultured rat microglia
[99,100]. Additionally, released factors from neurons
can also influence the survival of microglia. Fukui et al.
demonstrated that treatment with conditioned media
from mature neurons significantly induced the death of
microglial cells independent of LPS, while heated
neuron-conditioned media or low-calcium-ion media
prevented the death of microglia [101], indicating that
specific factors released from neurons exert detrimental
effects on microglia. It has been demonstrated that
microglial cells undergo apoptosis following peripheral
nerve injury [102-104] or in cases of experimental auto-
immune encephalomyelitis(EAE) [105]Injured neurons
induced either neuroprotective or neurotoxic behaviors
in microglia depending on the manner of injury
[91,106-109], providing strong evidence to support the
hypothesis of crosstalk between neurons and microglia.
Thus, microglia are not merely surveyors of brain tissue
but also receive and actively respond to signals from
neurons.
Crosstalk between astrocytes and microglia: reciprocal
influences
Although less obvious than the crosstalk with neurons,
the interactions between microglia and astrocytes are
far from simple and are also crucial for our understand-
ing of how microglia respond to their environment and
exert influence on neuronal degeneration or regener-
ation. Several studies have demonstrated the substantial
influence of astrocytes on microglial activation [110].
The induction of microglia by Trimethyltin or Borna
disease virus-infected neurons is dependent on the pres-
ence of astrocytes [111,112]. Astrocytes play neuroprotec-
tive roles by modulating microglial cell activity and
decreasing their cytotoxicity [113,114]. The expression of
IL-12 and the production of inducible nitric oxide syn-
thase (iNOS) in activated microglia have been reported to
be suppressed by astrocytes or conditioned media from
astrocytes [82,111,115-117], delineating the signals from
astrocytes that affect the activities of microglia. Further-
more, the communication between these two types of cells
is two-way; microglia both receive and give signals, as pro-
inflammatory cytokines released from microglia inhibit
gap junctions and down-regulate connexin 43 expression
in astrocytes [118-120], which enhances astrocyte survival.
In another study, comparative proteome analysis was per-
formed on astrocytes that were treated with conditioned
media from quiescent or activated microglia. Following
culture in activated-microglial media, the anti-oxidative
enzymes expressed in astrocytes were up-regulated, and
these astrocytes were protected against oxidative stress.
This result gave insight into the complex intercellular
events that take place during neurological disorders [121].
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system such as in neurodegeneration [122], microglia, acti-
vated earlier than astrocytes, promote astrocytic activation
through IL-1which is mostly from microglia [123]. On the
other hand, activated astrocytes not only facilitate activa-
tion of distant microglia via calcium wave [124,125], but
also inhibit microglial activities [126]. Additionally, it was
observed that activated-microglial-conditioned media
increased astroglial proliferation [127], down-regulated the
astroglial metabotropic glutamate receptor [128] and
induced astroglial brain-derived neurotrophic factor
(BDNF) and IL-6 gene expression [129]. Taken together,
the importance of microglial activities lies in that they not
only exert direct effects on neuronal survival, but they also
affect the responses of other supporting cells in the same
environment.
Microglia-T cell crosstalk: key determinants for the trend
of immune response
The entire immune response consists of the cooperation of
the innate and adaptive immune systems. In the brain, it
has been postulated that the beneficial or destructive out-
come of the local microglial (innate) response is determined
by a well-controlled dialogue between the innate and the
adaptive immune players, which are, in most cases, the
microglia and T cells. Activated T cells can cross the blood–
brain barrier and interact with resident microglia in the par-
enchyma [130]; these microglia have been characterized as
myeloid progenitor cells that can differentiate into macro-
phage-like or dendritic-like cells [131] and thus work cru-
cially as the principal APCs [85] in the CNS. Monsonego
et al. demonstrated that IFN-γ-treated microglia serve as ef-
ficient Aβ antigen-presenting cells (APCs) of both Aβ1-40
and Aβ1-42, mediating CD86-dependent proliferation of
Aβ-reactive T cells [132]. The activated T cells then exert
effects in the injured neural tissues by altering the reactive
microglial phenotypes and inducing the astrocytic expres-
sion of growth factors or modulating microglia to act as glu-
tamate scavengers [44] to improve neuronal survival
[133,134]. In a model for optic nerve injury, the passive
transfer of regulatory CD4+CD25+ T cells was either de-
structive or beneficial depending on the genetic background
of the mice tested, which determines the differential inter-
action of T cells with microglia and thus the different T cell-
mediated microglial phenotypes [133]. Kipnis even observed
that both the suppressor and the effector activities of T cells
could be mediated through dialogue with microglia in the
condition of neurodegneration [135], The entire scenario of
crosstalk between T cells and microglia could be described
as the following: microglia are initially activated by patho-
logical stimuli during acute or chronic injury to the brain; if
the activation occurs with the proper timing and mode and
is well-controlled, the activated microglia will work as APCs
[133] to stimulate Treg cells that eventually modulate themicroglial activation directly or indirectly and affect the mi-
lieu balance between neurotrophism and cytotoxicity
[44,136,137].
Whether microglial activation is neurotrophic or
neurotoxic is context-dependent
After considerable time and research, we have recognized
the “double-edged sword” nature of microglial cells. On
one hand, significant evidence from in vitro and in vivo
studies has associated neuronal injury with microglial acti-
vation [138-141]. This evidence results from an inflamma-
tory phenotype of microglia releasing neurotoxic factors,
mediators and reactive oxygen species [138-141]. On the
other hand, several other studies have highlighted the
beneficial and important roles of microglia in neuronal re-
generation, repair and neurogenesis [142-146]. These
seemingly paradoxical results cannot be directly compared,
because they come from different experimental sets that
vary in terms of the stimulus, timing of microglial activa-
tion and age of animals. Thus, whether microglia have
positive or negative effects on neuronal survival is context-
dependent.
Aging can result in microglial dysfunction and subsequent
neurotoxicity
There are studies suggesting that senescence in microglia
causes them to function abnormally and that the destructive
roles of activated microglia in the aged neurodegenerative
brain may result from age-associated microglia senescence,
causing a failure of the aged microglia to respond correctly
to stimuli [147,148] and eventually promoting neurodegen-
eration [149] (Figure 1). The most prominent and also the
initially identified feature of microglial senescence is the
morphological alteration described as “dystrophy” [150].
Characteristics of “dystrophic” microglia observed in the
aged brain include de-ramification (the loss of finely
branched cytoplasmic processes), cytoplasmic beading/
spheroid formation, shortened and twisted cytoplasmic pro-
cesses, and instances of partial or complete cytoplasmic
fragmentation [150]. Such dystrophic microglia were preva-
lent and extensively distributed in the brain of older human
subjects [150,151], whereas normally ramified microglial
morphology with only rare instances of dystrophic micro-
glia is observed in the young brain [148]. These observa-
tions provide initial evidence for the age-associated changes
in microglia in the healthy elderly brain. Telomere shorten-
ing, a marker of aging, has also been demonstrated in
microglia in the aged brain in Flanary’s study, who reported
that microglial cells in rats exhibit significant telomere
shortening and a reduction in telomerase activity during
normal aging [152]. More importantly, microglial senes-
cence is also manifested by functional alterations, such
as an altered inflammatory profile, increased immuno-
phenotypic expression, and the switch from neuroprotective
Figure 1 Age-primed microglia hypothesis of Parkinson’s disease. Microglia functions differentially in the young (left) and aged (right) brain.
Left: when facing pathogenic stimuli (large black dots), the healthy microglia in the young brain respond by releasing neurotrophic factors (small
yellow dots) to support the endangered dopaminergic neurons and limit neuronal damages. Right: in the aged brain oxidative stress and
inflammatory factors (small black dots), which damage the vulnerable dopaminergic neurons and eventually lead to neurodegeneration. (From
Luo et al.,2010 with permission).
Luo and Chen Translational Neurodegeneration 2012, 1:9 Page 6 of 13
http://www.translationalneurodegeneration.com/content/1/1/9in the young brain to neurotoxic in the aged brain upon
activation [147]. Also, the timing of microglial proliferation
and presentation in the injured aged brain is distinct from
that in the young brain. For example, Conde et al. reported
that microglial proliferation rates in the aged rat brain were
significantly higher than in the young rat brain four days
after axotomy of the facial nerve [148]. The distinct pattern
of the microglial response to injury in the aged brain has
also been recorded in the 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP)-induced model of neurotoxicity
[153], the model of controlled cortical impact (CCI) [154],
cortical stab injury [155]and transient retinal ischemia
[156]. Although more attention has been paid to the dys-
function of aged microglia, many critical questions remain
unanswered. Some of these questions are: whether the acti-
vated state of microglia in the aging brain is concurrent
with or secondary to microglial dystrophy; which specific
function of microglia is primarily affected by microglial
dystrophy, how it is affected and what is the direct conse-
quence of the affected function; and whether the deterior-
ation of a specific microglial function is more related toneurodegeneration than others. Clearly, more research is
needed to answer these questions.
The timing of activation is an indispensible determinant
of microglial function
Another important element that critically determines the
destructive or neuroprotective role of microglia is the
timing of their activation. Because large and very compli-
cated communications pathways exist between immuno-
competent cells and cytokines in the CNS, the timing of
microglial activation leads to diverse trends and out-
comes related to the entire inflammation event. In a
model of optic nerve crush injury, Shaked et al. found
that an earlier onset of phagocytic activity and antigen
presentation by microglia results in a resistance to injury
and neurons survived [133]; the early, moderate, transi-
ent and well-controlled activation of local microglia
caused them to function as APCs, leading to the com-
munication with Treg cells that subsequently proves to
be neuroprotective through the modulation of microglial
activation states [133]. In a multiple sclerosis (MS)
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[157], the inhibition of microglial activation through tPA
knockout (tissue plasminogen activator, an essential
element for microglia activation) leads to a delayed onset
of the disease but increased severity and delayed recov-
ery from the neurological dysfunction, which suggests
that microglial activation is harmful during the onset of
the disease but beneficial in the recovery phase [157].
Furthermore, when microglial activation was either sti-
mulated or inhibited at different stages, the disease pro-
gression was attenuated or exacerbated accordingly
[158]. For example, the inhibition of microglial activation
at EAE onset, rather than prior to EAE induction, mark-
edly decreased EAE progression, while the stimulation of
microglial activation prior to the onset of EAE promotes
lower-level EAE and an earlier recovery from symptoms.
Together, these findings suggest different roles for
microglial activation during various phases of the disease
and that different timing of microglial activation dramat-
ically affects whether microglia will be neuroprotective
or deleterious [158]. Similarly, in an oxygen-glucose
deprivation model, the time window of microglial neuro-
protection has been estimated to up to 48 hour after in-
jury, while the pre-stimulation of microglia with LPS
before the injury fails to induce microglial-mediated neu-
roprotection [86]. It has been proposed that the effects
of the early activation of microglia on disease progres-
sion could be beneficial through phagocytic activity and
antigen presentation, recruitment and interactions with
the adaptive immune response and the induction of pro-
tective autoimmunity [133]. Furthermore, the balance
between protective autoimmunity and autoimmune dis-
ease may be determined by the timing and intensity of
microglial activation [133]. As the immuno-competent
cells in the CNS, microglia are critical determinants of
the outcome of injury, and the timing of microglial acti-
vation appears to be crucial to the outcome of the injury.
Thus, any interference with microglial activation in
an attempt to affect the disease course clearly must be
temporally-restricted.
Activation states of microglia
Two distinct phenotypes of macrophages have long been
known to play different roles in the inflammatory con-
text. Classically-activated macrophages, characterized by
the involvement of T Helper type 1 (Th-1) cytokines
such as interferon-γ, promote the release of various pro-
inflammatory cytokines and thus exacerbate the inflam-
mation. Alternatively, activated macrophages predomin-
ate in the T Helper type 2 (Th-2) microenvironment and
tend to soothe the inflammation. Thus, the behavior of
macrophages is dictated by their phenotype, which may
eventually affect the beneficial or detrimental roles of
macrophages during inflammation. Similarly, researchover the past few years has established that microglia do
not constitute a single, uniform cell population, but ra-
ther comprise a family of cells with diverse phenotypes;
some are neuroprotective while others are destructive
[92]. So far, three distinct functions have been proposed
for microglia. The first is the classical activation state of
microglia, which, accompanied by the induction of
receptors that participate in the innate immune response
[159], is responsible for the pro-inflammatory milieu,
and has been linked to neurotoxic effects in the brain.
The second is alternatively activated microglia, which are
associated with the production of anti-inflammatory
cytokines in the resolution phase of the inflammatory re-
sponse. Recently, the third activation state of microglia
has been identified: it overlaps with and is complemen-
tary to the alternative activation and is called acquired
deactivation [160,161]. This is another activation state
that promotes immunosuppression and is associated
with the anti-inflammatory and functional repair pheno-
type .Both alternative activation and acquired deactiva-
tion down-regulate innate immune responses and have
similar gene profiles; the most prominent difference is
that acquired deactivation is induced by the exposure of
microglia to apoptotic cells or to TGF-β or IL-10, while
IL-4 and IL-13 induce alternative activation [160,161]. It
has been observed that multiple activation states of
microglia coexist in certain chronic inflammations due
to parasitic disease [162], in which the balance between
classical activation and alternative activation/acquired
deactivation states is of “benefit” to both host and parasite:
the host benefits from reduced self-damage, and the para-
site eventually survives within the host. Neurodegenerative
disorders are also associated with chronic inflammation and
the coexistence of various activation states. For example, in
AD, some levels of classical activation may be required to
limit the brain levels of Aβ despite the risk of self-damage
[163], while alternative activation of microglia in AD may
foster the protection of the surrounding tissue from im-
mune damage even though it may facilitate Aβ deposits.
Similar studies [164-166] have shown that the immune cells
in the vicinity of amyloid deposits in AD express mRNA
and proteins for pro-inflammatory cytokines, leading to the
hypothesis that microglia demonstrate classical activation in
AD, while Colton et al. found increased mRNA expression
of alternative activation-associated gene profiles in microglia
in both the AD brain and an AD mouse model [167], sug-
gesting the presence of multiple activation states of micro-
glia during neurodegeneration. However, the recognition of
heterogeneous phenotypes of microglia only raises more
questions: what instructs microglia to acquire a particular
phenotype; can any conversion occur between these pheno-
types; and is it possible to avoid or at least change the com-
mitment to a destructive phenotype? All of these questions
are difficult to answer with our current knowledge of
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The stimulus type is another turning point for microglial
function
As an active sensor in the brain, microglia respond to
even minor stimuli; however, different types of stimula-
tion may also lead to different actions of microglia and
thus be either harmful or beneficial to neuronal survival.
In a neonatal mouse MPTP-induced brain injury model,
microglia activated by systemic administration of LPS
were shown to be neuroprotective. In contrast to the
MPTP model, LPS-activated microglia in neonatal mice
receiving a stereotaxic injection of ethanol into the stri-
atum were shown to be neurotoxic, and systemic LPS
administration in the ethanol-injury model caused a
marked increase both in the volume of necrotic lesions
and in the number of degenerating neurons in the stri-
atum [168]. Even with the same stimuli, the degree can
also determine microglial release of toxic versus protective
effectors [169]; neurotoxic cytokines and ROS were
released from microglia only in response to mild neuronal
injuries, while trophic microglial effectors such as BDNF
and GDNF were up-regulated in response to all degrees of
neuronal injury [169]. Additionally, different types of pain
resulted in differing activations of microglia [170].
So far, what we know is that not all microglia respond in
the same way, even to the same stimulus, and microglial
function is tailored in a context-specific manner [171]. Nu-
merous elements are involved in this context; most likely
there are many more beyond what we have discussed here.
Identifying these elements and clarifying their interactions
or crosstalk with microglia is essential before we are able
to design a strategy to control inflammation through the
manipulation of microglia. The simple therapy of inhibit-
ing all microglia without differentiating their function in a
context-dependent manner surely should be abandoned.
Microglia and neurogenesis
It has been long recognized that the birth of new neurons
within the postnatal brain continues throughout life and
remains as a potential source of replacement cells in the
CNS for the treatment of disease. The microenvironment
or the niche in which neural progenitor cells live critically
influences the process of neurogenesis, which spans several
steps including the proliferation of stem or progenitor cells;
the survival of immature or mature neurons; the migration
of new neuroblasts to their appropriate locations; and the
differentiation of neuroblasts to a neuronal phenotype and
the construction of synaptic connectivity [172]. As an im-
portant component of the brain microenvironment and due
to their invariant participation in most pathological pro-
cesses in the CNS, microglia are increasingly implicated as
a potential non-neural regulator of neurogenesis, asdemonstrated by circumstantial evidence [144,172]. How-
ever, just as in the debate over the neuroprotective or
neurotoxic nature of microglial activation, whether micro-
glia support or damage the survival and development of
neural progenitor cells also remains controversial. On one
hand, microglia were shown to play instructive roles during
postnatal neurogenesis in the neurogenic niche either by in-
fluencing the differentiation of stem cells toward a neuronal
phenotype or by directing their migration [144,173-175].
On the other hand, multiple studies have demonstrated the
deleterious effect of microglial activation on neurogenesis
[176,177] and the effective restoration of neurogenesis
though the blockade of microglial activation.
In the two situations of neurogenesis and neuronal
survival, similar factors are shared, leading microglia to
take supportive or detrimental roles. Among these fac-
tors, the most prominent is the microglial activation
phenotype that is associated with different cytokine pro-
files. When acutely activated by either LPS or injury,
microglia that release the pro-inflammatory cytokines
IL-6, TNF-α or IL-1β usually down-regulate the differen-
tiation or proliferation of neural stem cells or induce the
aberrant migration of newborn neurons [178]. This
group of inflammatory cytokines has been proven to in-
hibit neurogenesis [176,177,179]; conversely, blocking
antibodies to these pro-inflammatory cytokines (such as
IL-6 [177]) or the use of monocycline to mitigate the
microglial activation simply restores neurogenesis [176].
In contrast, microglia that are activated by anti-inflamma-
tory cytokines such as IL-4 or TGF-β increase neurogen-
esis in vitro or the differentiation of neural stem cells
(NSCs) in vivo [180,181]. Neurotrophins, such as IGF-1,
were identified [181] in anti-inflammatory cytokine-
activated microglia and were proposed to be one of the
mechanisms underlying this pro-neurogenic activity of
microglia [182,183]. However, just like the dual roles in
neuroprotection, whether a specific cytokine-activated
microglial cell will take a pro- or anti-neurogenic role is
also context-dependent. For example, microglial cells
activated by IFN-γ, a pro-inflammatory cytokine can be
neurotoxic or supportive of neurogenesis, depending on
the concentration of IFN-γ [184]. TGF-β, which is con-
sidered to be beneficial to neurogenesis, can actually
exert a negative influence on neurogenesis when it is
chronically produced in the aged brain [185]. Additionally,
if other cytokines exist in the same niche simultaneously,
the outcome will be determined by the balance among the
various cytokines; some authors have concluded that acti-
vated microglia are not pro- or anti-neurogenic per se, but
the balance between pro- and anti-inflammatory secreted
molecules influences the final effect of microglial activa-
tion [172,180]. However, in which situations the microglia
will release pro- or anti-inflammatory cytokines is compli-
cated and is affected by multiple factors such as the injury
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with other regulating components, including neural pre-
cursors; this is similar to the question of whether microglia
will be neuroprotective or neurotoxic. Most likely the
same inflammatory scenario that induces neurodegenera-
tion would also inhibit neurogenesis, while a situation that
favors neuronal survival would also support neurogenesis.
Interestingly, even in a high-inflammation environment,
such as two days after a Trimethyltin-induced acute injury
in the hippocampus, significant neurogenesis can be
detected [186,187], suggesting a complicated system of
neurogenesis regulation beyond the inflammation
scenario.
Cumulative studies have found an age-related decline
in neurogenesis, both in the aged adult and in the dis-
eased brain. Because aging may contribute to microglial
dysfunction and neurotoxicity, as we discussed previ-
ously in this review, one could assume that microglial
dysfunction may also be involved in the downregulation
of neurogenesis in the aged or diseased brain [188,189].
Even though very few studies have focused on the effect
of microglial dysfunction on neurogenesis, we can still
find a clue from Zhu’s study that the difference in micro-
glia function patterns between the immature and juvenile
brain might be related to a decrease in neurogenesis in
the juvenile brain [190]; however, stronger evidence from
the direct comparison of microglia-associated neurogen-
esis between aged and young brains is needed to support
this view.
Another important element regulating the activities of
microglia is the T cell, which comes from the peripheral
adaptive immune system and enters the CNS by extravasat-
ing across the endothelium of the choroid plexus into the
cerebrospinal fluid [191]. The interaction of T cells with
microglia in the injured spinal cord correlates with
enhanced neuronal survival [184], and rapidly recruited T
cells in the middle cerebral artery obstruction (MCAO)
model increased hippocampal and cortical neurogenesis by
modulating the microglial response and through the pro-
duction of IGF in the sub-acute phase [192]. Hippocampal
neurogenesis was associated with the recruitment of T cells
and microglial activation. Immune-deficient mice show
impaired neurogenesis in the hippocampus, but this defi-
ciency was attenuated and neurogenesis boosted by T cells
recognizing a specific CNS antigen [193]. The cellular
source of IFN-γ and IL-4 in vivo is likely to be T cells, there-
fore it is reasonable to assume that the T cell-mediated im-
mune response is an integral part of the regulation of
microglial phenotype or function, and thus can influence
neuronal survival or neurogenesis directly or indirectly.
Conclusion
From an increasing number of studies of diverse micro-
glial activity in different experimental sets, we arebeginning to appreciate the heterogeneity of microglial
functions that have either beneficial or detrimental roles
in specific physiological or pathological environments.
Whether microglia are committed to one function from
the very beginning or if there is any conversion between
different phenotypes remains elusive and the factors that
initiate this commitment or promote its conversion are
far from being clarified. Due to the invariant critical par-
ticipation of microglia in most diseases, ongoing research
to uncover these questions is warranted; before we are
sure about the answer, any potential strategies targeting
microglia to manipulate inflammation and modify a dis-
ease course are unrealistic.
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